nodes	percent_of_prediction	percent_of_DWPC	metapath
Vismodegib—skin cancer—melanoma	0.349	1	CtDrD
Vismodegib—Etoricoxib—Vemurafenib—melanoma	0.319	1	CrCrCtD
Vismodegib—ALB—melanoma	0.0496	0.512	CbGaD
Vismodegib—ORM1—Vemurafenib—melanoma	0.049	0.304	CbGbCtD
Vismodegib—ABCB1—melanoma	0.0473	0.488	CbGaD
Vismodegib—ABCG2—Vemurafenib—melanoma	0.0299	0.186	CbGbCtD
Vismodegib—ALB—Vemurafenib—melanoma	0.0206	0.128	CbGbCtD
Vismodegib—ABCG2—Dactinomycin—melanoma	0.0199	0.123	CbGbCtD
Vismodegib—CYP3A4—Temozolomide—melanoma	0.0118	0.0732	CbGbCtD
Vismodegib—ABCG2—Docetaxel—melanoma	0.0103	0.0637	CbGbCtD
Vismodegib—ABCB1—Dactinomycin—melanoma	0.00716	0.0445	CbGbCtD
Vismodegib—CYP3A4—Vemurafenib—melanoma	0.00646	0.0401	CbGbCtD
Vismodegib—ABCB1—Docetaxel—melanoma	0.0037	0.023	CbGbCtD
Vismodegib—SHH—appendage—melanoma	0.00339	0.274	CbGeAlD
Vismodegib—SHH—skin epidermis—melanoma	0.00282	0.228	CbGeAlD
Vismodegib—CYP3A4—Docetaxel—melanoma	0.00222	0.0138	CbGbCtD
Vismodegib—SHH—hair follicle—melanoma	0.00201	0.163	CbGeAlD
Vismodegib—SHH—skin of body—melanoma	0.000875	0.0706	CbGeAlD
Vismodegib—Neoplasm malignant—Vemurafenib—melanoma	0.000667	0.0337	CcSEcCtD
Vismodegib—SMO—skin of body—melanoma	0.000612	0.0494	CbGeAlD
Vismodegib—Musculoskeletal pain—Vemurafenib—melanoma	0.000577	0.0291	CcSEcCtD
Vismodegib—SHH—head—melanoma	0.000571	0.046	CbGeAlD
Vismodegib—Azotaemia—Carmustine—melanoma	0.000566	0.0286	CcSEcCtD
Vismodegib—SMO—mammalian vulva—melanoma	0.000558	0.045	CbGeAlD
Vismodegib—Pain in extremity—Vemurafenib—melanoma	0.000414	0.0209	CcSEcCtD
Vismodegib—SMO—head—melanoma	0.000399	0.0322	CbGeAlD
Vismodegib—Sorafenib—FLT1—melanoma	0.000368	0.197	CrCbGaD
Vismodegib—Amenorrhoea—Temozolomide—melanoma	0.000331	0.0167	CcSEcCtD
Vismodegib—Weight decreased—Vemurafenib—melanoma	0.000323	0.0163	CcSEcCtD
Vismodegib—Hepatic enzyme increased—Temozolomide—melanoma	0.000308	0.0155	CcSEcCtD
Vismodegib—Sorafenib—PDGFRA—melanoma	0.000297	0.159	CrCbGaD
Vismodegib—Musculoskeletal pain—Temozolomide—melanoma	0.000295	0.0149	CcSEcCtD
Vismodegib—Phosphatase alkaline increased—Temozolomide—melanoma	0.000291	0.0147	CcSEcCtD
Vismodegib—Connective tissue disorder—Vemurafenib—melanoma	0.000281	0.0142	CcSEcCtD
Vismodegib—SMO—lymph node—melanoma	0.00028	0.0225	CbGeAlD
Vismodegib—Sorafenib—BRAF—melanoma	0.000272	0.145	CrCbGaD
Vismodegib—Alopecia—Vemurafenib—melanoma	0.000253	0.0128	CcSEcCtD
Vismodegib—Malnutrition—Vemurafenib—melanoma	0.000249	0.0126	CcSEcCtD
Vismodegib—Dysgeusia—Vemurafenib—melanoma	0.000244	0.0123	CcSEcCtD
Vismodegib—Blood alkaline phosphatase increased—Temozolomide—melanoma	0.000243	0.0123	CcSEcCtD
Vismodegib—Back pain—Vemurafenib—melanoma	0.000241	0.0122	CcSEcCtD
Vismodegib—Ageusia—Docetaxel—melanoma	0.000239	0.0121	CcSEcCtD
Vismodegib—Sorafenib—KDR—melanoma	0.000231	0.123	CrCbGaD
Vismodegib—Amenorrhoea—Docetaxel—melanoma	0.00022	0.0111	CcSEcCtD
Vismodegib—Hyponatraemia—Carmustine—melanoma	0.00022	0.0111	CcSEcCtD
Vismodegib—Sorafenib—KIT—melanoma	0.000218	0.116	CrCbGaD
Vismodegib—Arthralgia—Vemurafenib—melanoma	0.000212	0.0107	CcSEcCtD
Vismodegib—Myalgia—Vemurafenib—melanoma	0.000212	0.0107	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—melanoma	0.000211	0.0106	CcSEcCtD
Vismodegib—Aspartate aminotransferase increased—Dactinomycin—melanoma	0.000211	0.0106	CcSEcCtD
Vismodegib—Nervous system disorder—Vemurafenib—melanoma	0.000199	0.0101	CcSEcCtD
Vismodegib—Hypokalaemia—Carmustine—melanoma	0.000199	0.01	CcSEcCtD
Vismodegib—Skin disorder—Vemurafenib—melanoma	0.000198	0.00997	CcSEcCtD
Vismodegib—Dehydration—Temozolomide—melanoma	0.000197	0.00992	CcSEcCtD
Vismodegib—Weight decreased—Bleomycin—melanoma	0.000196	0.00989	CcSEcCtD
Vismodegib—Phosphatase alkaline increased—Docetaxel—melanoma	0.000194	0.00978	CcSEcCtD
Vismodegib—Hypokalaemia—Temozolomide—melanoma	0.000192	0.00971	CcSEcCtD
Vismodegib—Breast disorder—Temozolomide—melanoma	0.000191	0.00964	CcSEcCtD
Vismodegib—Aspartate aminotransferase increased—Temozolomide—melanoma	0.00019	0.00961	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Vemurafenib—melanoma	0.000185	0.00935	CcSEcCtD
Vismodegib—Decreased appetite—Vemurafenib—melanoma	0.000177	0.00892	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Vemurafenib—melanoma	0.000176	0.00886	CcSEcCtD
Vismodegib—Fatigue—Vemurafenib—melanoma	0.000175	0.00885	CcSEcCtD
Vismodegib—Constipation—Vemurafenib—melanoma	0.000174	0.00878	CcSEcCtD
Vismodegib—ABCB1—blood vessel—melanoma	0.000171	0.0138	CbGeAlD
Vismodegib—Weight decreased—Temozolomide—melanoma	0.000165	0.00834	CcSEcCtD
Vismodegib—Blood alkaline phosphatase increased—Docetaxel—melanoma	0.000162	0.00816	CcSEcCtD
Vismodegib—Alopecia—Bleomycin—melanoma	0.000153	0.00773	CcSEcCtD
Vismodegib—Connective tissue disorder—Carmustine—melanoma	0.000149	0.00751	CcSEcCtD
Vismodegib—Sulfasalazine—PPARG—melanoma	0.000148	0.0791	CrCbGaD
Vismodegib—ABCG2—mammalian vulva—melanoma	0.000146	0.0118	CbGeAlD
Vismodegib—Asthenia—Vemurafenib—melanoma	0.000146	0.00736	CcSEcCtD
Vismodegib—Pruritus—Vemurafenib—melanoma	0.000144	0.00726	CcSEcCtD
Vismodegib—Connective tissue disorder—Temozolomide—melanoma	0.000144	0.00725	CcSEcCtD
Vismodegib—Alopecia—Dactinomycin—melanoma	0.000143	0.00721	CcSEcCtD
Vismodegib—Hyponatraemia—Docetaxel—melanoma	0.000141	0.00713	CcSEcCtD
Vismodegib—Pain in extremity—Docetaxel—melanoma	0.000141	0.0071	CcSEcCtD
Vismodegib—Diarrhoea—Vemurafenib—melanoma	0.000139	0.00702	CcSEcCtD
Vismodegib—Alopecia—Carmustine—melanoma	0.000134	0.00675	CcSEcCtD
Vismodegib—Malnutrition—Carmustine—melanoma	0.000132	0.00665	CcSEcCtD
Vismodegib—Dehydration—Docetaxel—melanoma	0.000131	0.0066	CcSEcCtD
Vismodegib—Vomiting—Vemurafenib—melanoma	0.000129	0.00652	CcSEcCtD
Vismodegib—Alopecia—Temozolomide—melanoma	0.000129	0.00652	CcSEcCtD
Vismodegib—Myalgia—Bleomycin—melanoma	0.000129	0.00649	CcSEcCtD
Vismodegib—Abdominal pain upper—Docetaxel—melanoma	0.000128	0.00648	CcSEcCtD
Vismodegib—Rash—Vemurafenib—melanoma	0.000128	0.00647	CcSEcCtD
Vismodegib—Dermatitis—Vemurafenib—melanoma	0.000128	0.00646	CcSEcCtD
Vismodegib—Back pain—Carmustine—melanoma	0.000127	0.00643	CcSEcCtD
Vismodegib—Malnutrition—Temozolomide—melanoma	0.000127	0.00643	CcSEcCtD
Vismodegib—Breast disorder—Docetaxel—melanoma	0.000127	0.00641	CcSEcCtD
Vismodegib—Aspartate aminotransferase increased—Docetaxel—melanoma	0.000127	0.00639	CcSEcCtD
Vismodegib—Dysgeusia—Temozolomide—melanoma	0.000125	0.00629	CcSEcCtD
Vismodegib—Back pain—Temozolomide—melanoma	0.000123	0.00622	CcSEcCtD
Vismodegib—ORM1—lymph node—melanoma	0.000122	0.00985	CbGeAlD
Vismodegib—Nausea—Vemurafenib—melanoma	0.000121	0.0061	CcSEcCtD
Vismodegib—Myalgia—Dactinomycin—melanoma	0.00012	0.00605	CcSEcCtD
Vismodegib—Tolvaptan—ABCB1—melanoma	0.000119	0.0636	CrCbGaD
Vismodegib—Musculoskeletal discomfort—Bleomycin—melanoma	0.000112	0.00566	CcSEcCtD
Vismodegib—Myalgia—Carmustine—melanoma	0.000112	0.00566	CcSEcCtD
Vismodegib—Weight decreased—Docetaxel—melanoma	0.00011	0.00555	CcSEcCtD
Vismodegib—Myalgia—Temozolomide—melanoma	0.000108	0.00547	CcSEcCtD
Vismodegib—Arthralgia—Temozolomide—melanoma	0.000108	0.00547	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.000108	0.00543	CcSEcCtD
Vismodegib—ALB—lymph node—melanoma	0.000107	0.00864	CbGeAlD
Vismodegib—Decreased appetite—Bleomycin—melanoma	0.000107	0.0054	CcSEcCtD
Vismodegib—Etoricoxib—PTGS2—melanoma	0.000106	0.0567	CrCbGaD
Vismodegib—Pain—Bleomycin—melanoma	0.000105	0.00532	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Dactinomycin—melanoma	0.000105	0.00528	CcSEcCtD
Vismodegib—Nervous system disorder—Temozolomide—melanoma	0.000102	0.00514	CcSEcCtD
Vismodegib—Skin disorder—Temozolomide—melanoma	0.000101	0.00509	CcSEcCtD
Vismodegib—Decreased appetite—Dactinomycin—melanoma	9.99e-05	0.00504	CcSEcCtD
Vismodegib—Fatigue—Dactinomycin—melanoma	9.91e-05	0.005	CcSEcCtD
Vismodegib—Pain—Dactinomycin—melanoma	9.83e-05	0.00496	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Carmustine—melanoma	9.8e-05	0.00494	CcSEcCtD
Vismodegib—Connective tissue disorder—Docetaxel—melanoma	9.56e-05	0.00482	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Temozolomide—melanoma	9.47e-05	0.00478	CcSEcCtD
Vismodegib—Gastrointestinal pain—Dactinomycin—melanoma	9.4e-05	0.00474	CcSEcCtD
Vismodegib—Decreased appetite—Carmustine—melanoma	9.35e-05	0.00472	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Carmustine—melanoma	9.28e-05	0.00469	CcSEcCtD
Vismodegib—Pain—Carmustine—melanoma	9.2e-05	0.00464	CcSEcCtD
Vismodegib—Constipation—Carmustine—melanoma	9.2e-05	0.00464	CcSEcCtD
Vismodegib—Dyspepsia—Temozolomide—melanoma	9.15e-05	0.00462	CcSEcCtD
Vismodegib—Abdominal pain—Dactinomycin—melanoma	9.08e-05	0.00458	CcSEcCtD
Vismodegib—Decreased appetite—Temozolomide—melanoma	9.03e-05	0.00456	CcSEcCtD
Vismodegib—ABCB1—retina—melanoma	9e-05	0.00726	CbGeAlD
Vismodegib—Gastrointestinal disorder—Temozolomide—melanoma	8.97e-05	0.00453	CcSEcCtD
Vismodegib—Fatigue—Temozolomide—melanoma	8.96e-05	0.00452	CcSEcCtD
Vismodegib—Pain—Temozolomide—melanoma	8.89e-05	0.00449	CcSEcCtD
Vismodegib—Constipation—Temozolomide—melanoma	8.89e-05	0.00449	CcSEcCtD
Vismodegib—Asthenia—Bleomycin—melanoma	8.84e-05	0.00446	CcSEcCtD
Vismodegib—Gastrointestinal pain—Carmustine—melanoma	8.79e-05	0.00444	CcSEcCtD
Vismodegib—Pruritus—Bleomycin—melanoma	8.72e-05	0.0044	CcSEcCtD
Vismodegib—Alopecia—Docetaxel—melanoma	8.6e-05	0.00434	CcSEcCtD
Vismodegib—Abdominal pain—Carmustine—melanoma	8.5e-05	0.00429	CcSEcCtD
Vismodegib—Gastrointestinal pain—Temozolomide—melanoma	8.5e-05	0.00429	CcSEcCtD
Vismodegib—Malnutrition—Docetaxel—melanoma	8.47e-05	0.00427	CcSEcCtD
Vismodegib—Dysgeusia—Docetaxel—melanoma	8.29e-05	0.00419	CcSEcCtD
Vismodegib—Asthenia—Dactinomycin—melanoma	8.24e-05	0.00416	CcSEcCtD
Vismodegib—Abdominal pain—Temozolomide—melanoma	8.21e-05	0.00415	CcSEcCtD
Vismodegib—Back pain—Docetaxel—melanoma	8.19e-05	0.00413	CcSEcCtD
Vismodegib—Muscle spasms—Docetaxel—melanoma	8.14e-05	0.00411	CcSEcCtD
Vismodegib—Diarrhoea—Dactinomycin—melanoma	7.86e-05	0.00397	CcSEcCtD
Vismodegib—Vomiting—Bleomycin—melanoma	7.83e-05	0.00395	CcSEcCtD
Vismodegib—Rash—Bleomycin—melanoma	7.77e-05	0.00392	CcSEcCtD
Vismodegib—Dermatitis—Bleomycin—melanoma	7.76e-05	0.00392	CcSEcCtD
Vismodegib—Asthenia—Carmustine—melanoma	7.72e-05	0.00389	CcSEcCtD
Vismodegib—Asthenia—Temozolomide—melanoma	7.46e-05	0.00376	CcSEcCtD
Vismodegib—Diarrhoea—Carmustine—melanoma	7.36e-05	0.00371	CcSEcCtD
Vismodegib—Pruritus—Temozolomide—melanoma	7.35e-05	0.00371	CcSEcCtD
Vismodegib—ABCG2—lymph node—melanoma	7.32e-05	0.0059	CbGeAlD
Vismodegib—Nausea—Bleomycin—melanoma	7.32e-05	0.00369	CcSEcCtD
Vismodegib—Vomiting—Dactinomycin—melanoma	7.31e-05	0.00369	CcSEcCtD
Vismodegib—Rash—Dactinomycin—melanoma	7.24e-05	0.00366	CcSEcCtD
Vismodegib—Myalgia—Docetaxel—melanoma	7.21e-05	0.00364	CcSEcCtD
Vismodegib—Arthralgia—Docetaxel—melanoma	7.21e-05	0.00364	CcSEcCtD
Vismodegib—ABCB1—mammalian vulva—melanoma	7.2e-05	0.00581	CbGeAlD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	7.16e-05	0.00361	CcSEcCtD
Vismodegib—Diarrhoea—Temozolomide—melanoma	7.11e-05	0.00359	CcSEcCtD
Vismodegib—Vomiting—Carmustine—melanoma	6.84e-05	0.00345	CcSEcCtD
Vismodegib—Nausea—Dactinomycin—melanoma	6.82e-05	0.00344	CcSEcCtD
Vismodegib—Rash—Carmustine—melanoma	6.78e-05	0.00342	CcSEcCtD
Vismodegib—Nervous system disorder—Docetaxel—melanoma	6.78e-05	0.00342	CcSEcCtD
Vismodegib—Dermatitis—Carmustine—melanoma	6.77e-05	0.00342	CcSEcCtD
Vismodegib—Skin disorder—Docetaxel—melanoma	6.71e-05	0.00339	CcSEcCtD
Vismodegib—Vomiting—Temozolomide—melanoma	6.61e-05	0.00333	CcSEcCtD
Vismodegib—Rash—Temozolomide—melanoma	6.55e-05	0.00331	CcSEcCtD
Vismodegib—Dermatitis—Temozolomide—melanoma	6.55e-05	0.0033	CcSEcCtD
Vismodegib—Nausea—Carmustine—melanoma	6.39e-05	0.00322	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Docetaxel—melanoma	6.3e-05	0.00318	CcSEcCtD
Vismodegib—Sulfasalazine—PTGS2—melanoma	6.26e-05	0.0334	CrCbGaD
Vismodegib—Nausea—Temozolomide—melanoma	6.17e-05	0.00312	CcSEcCtD
Vismodegib—Dyspepsia—Docetaxel—melanoma	6.08e-05	0.00307	CcSEcCtD
Vismodegib—Decreased appetite—Docetaxel—melanoma	6.01e-05	0.00303	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Docetaxel—melanoma	5.97e-05	0.00301	CcSEcCtD
Vismodegib—Fatigue—Docetaxel—melanoma	5.96e-05	0.00301	CcSEcCtD
Vismodegib—Pain—Docetaxel—melanoma	5.91e-05	0.00298	CcSEcCtD
Vismodegib—Constipation—Docetaxel—melanoma	5.91e-05	0.00298	CcSEcCtD
Vismodegib—Gastrointestinal pain—Docetaxel—melanoma	5.65e-05	0.00285	CcSEcCtD
Vismodegib—Abdominal pain—Docetaxel—melanoma	5.46e-05	0.00276	CcSEcCtD
Vismodegib—ABCB1—head—melanoma	5.15e-05	0.00416	CbGeAlD
Vismodegib—Sorafenib—ABCB1—melanoma	5.02e-05	0.0268	CrCbGaD
Vismodegib—Asthenia—Docetaxel—melanoma	4.96e-05	0.0025	CcSEcCtD
Vismodegib—Pruritus—Docetaxel—melanoma	4.89e-05	0.00247	CcSEcCtD
Vismodegib—Diarrhoea—Docetaxel—melanoma	4.73e-05	0.00239	CcSEcCtD
Vismodegib—Vomiting—Docetaxel—melanoma	4.39e-05	0.00222	CcSEcCtD
Vismodegib—Rash—Docetaxel—melanoma	4.36e-05	0.0022	CcSEcCtD
Vismodegib—Dermatitis—Docetaxel—melanoma	4.35e-05	0.0022	CcSEcCtD
Vismodegib—Nausea—Docetaxel—melanoma	4.1e-05	0.00207	CcSEcCtD
Vismodegib—ABCB1—lymph node—melanoma	3.61e-05	0.00291	CbGeAlD
Vismodegib—ABCG2—Metabolism—SLC5A5—melanoma	3.69e-06	9.14e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—RAC1—melanoma	3.66e-06	9.05e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—CUBN—melanoma	3.64e-06	9.02e-05	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—MAPK1—melanoma	3.64e-06	9.01e-05	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—EGFR—melanoma	3.64e-06	9.01e-05	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—KRAS—melanoma	3.63e-06	8.98e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—CSPG4—melanoma	3.61e-06	8.93e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—BSG—melanoma	3.61e-06	8.93e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—SDHD—melanoma	3.61e-06	8.93e-05	CbGpPWpGaD
Vismodegib—ALB—Platelet activation, signaling and aggregation—VEGFA—melanoma	3.58e-06	8.88e-05	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—GNAQ—melanoma	3.57e-06	8.83e-05	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—CD44—melanoma	3.57e-06	8.83e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—MMP1—melanoma	3.54e-06	8.76e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—PHGDH—melanoma	3.54e-06	8.76e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—LUM—melanoma	3.54e-06	8.76e-05	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—melanoma	3.53e-06	8.74e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—SDHD—melanoma	3.52e-06	8.71e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—CSPG4—melanoma	3.52e-06	8.71e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—BSG—melanoma	3.52e-06	8.71e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—GPAM—melanoma	3.49e-06	8.65e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—CDK2—melanoma	3.47e-06	8.6e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—HPSE—melanoma	3.47e-06	8.59e-05	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—KRAS—melanoma	3.44e-06	8.51e-05	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—CYP1B1—melanoma	3.42e-06	8.47e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—GPAM—melanoma	3.41e-06	8.44e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—CUBN—melanoma	3.4e-06	8.43e-05	CbGpPWpGaD
Vismodegib—ALB—Platelet activation, signaling and aggregation—MAPK3—melanoma	3.39e-06	8.4e-05	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—melanoma	3.34e-06	8.27e-05	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—PIK3CA—melanoma	3.33e-06	8.25e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—PLA2G6—melanoma	3.33e-06	8.24e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—PLA2G6—melanoma	3.31e-06	8.19e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—BSG—melanoma	3.29e-06	8.14e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—SDHD—melanoma	3.29e-06	8.14e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—CSPG4—melanoma	3.29e-06	8.14e-05	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—melanoma	3.25e-06	8.04e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—FN1—melanoma	3.23e-06	7.99e-05	CbGpPWpGaD
Vismodegib—ALB—Platelet activation, signaling and aggregation—MAPK1—melanoma	3.23e-06	7.99e-05	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—TP53—melanoma	3.22e-06	7.98e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—NOS2—melanoma	3.19e-06	7.9e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—GPAM—melanoma	3.18e-06	7.88e-05	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—melanoma	3.18e-06	7.87e-05	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—melanoma	3.18e-06	7.86e-05	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—PIK3CA—melanoma	3.16e-06	7.82e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—PIK3CG—melanoma	3.09e-06	7.65e-05	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—HRAS—melanoma	3.08e-06	7.63e-05	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—TP53—melanoma	3.05e-06	7.57e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—EGF—melanoma	3.05e-06	7.56e-05	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—melanoma	3.02e-06	7.49e-05	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—melanoma	3e-06	7.43e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—VCAN—melanoma	2.99e-06	7.4e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—VCAN—melanoma	2.97e-06	7.36e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—PLA2G6—melanoma	2.97e-06	7.35e-05	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—IL6—melanoma	2.95e-06	7.3e-05	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—HRAS—melanoma	2.92e-06	7.23e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—PLA2G6—melanoma	2.9e-06	7.18e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—PLCB4—melanoma	2.86e-06	7.08e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CG—melanoma	2.83e-06	7e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—IGF1—melanoma	2.83e-06	7e-05	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—ABCB1—melanoma	2.82e-06	6.97e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism of lipids and lipoproteins—PIK3CG—melanoma	2.81e-06	6.96e-05	CbGpPWpGaD
Vismodegib—ALB—Platelet activation, signaling and aggregation—PIK3CA—melanoma	2.8e-06	6.93e-05	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—IL6—melanoma	2.8e-06	6.92e-05	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—melanoma	2.76e-06	6.83e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—melanoma	2.73e-06	6.76e-05	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—AKT1—melanoma	2.72e-06	6.74e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—PIK3CD—melanoma	2.72e-06	6.72e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism of lipids and lipoproteins—PPARG—melanoma	2.71e-06	6.72e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—PLA2G6—melanoma	2.71e-06	6.7e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—PIP4K2A—melanoma	2.69e-06	6.66e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—SLC6A11—melanoma	2.69e-06	6.66e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—VCAN—melanoma	2.67e-06	6.6e-05	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—melanoma	2.67e-06	6.6e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—MTAP—melanoma	2.62e-06	6.48e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—VCAN—melanoma	2.6e-06	6.45e-05	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—PRKCA—melanoma	2.59e-06	6.42e-05	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—AKT1—melanoma	2.58e-06	6.39e-05	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—ERCC2—melanoma	2.57e-06	6.36e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—melanoma	2.52e-06	6.25e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—CYP17A1—melanoma	2.52e-06	6.24e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—CYP17A1—melanoma	2.51e-06	6.21e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	2.49e-06	6.16e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	2.47e-06	6.12e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism of lipids and lipoproteins—ALB—melanoma	2.45e-06	6.08e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—melanoma	2.44e-06	6.03e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—VCAN—melanoma	2.43e-06	6.02e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—GNA11—melanoma	2.38e-06	5.9e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—GNA11—melanoma	2.37e-06	5.86e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—PIK3CB—melanoma	2.37e-06	5.86e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—LUM—melanoma	2.33e-06	5.78e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—PHGDH—melanoma	2.33e-06	5.78e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—FASN—melanoma	2.33e-06	5.77e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—FASN—melanoma	2.32e-06	5.74e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—melanoma	2.3e-06	5.7e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—SLC5A5—melanoma	2.29e-06	5.68e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—HPSE—melanoma	2.29e-06	5.66e-05	CbGpPWpGaD
Vismodegib—ALB—Platelet activation, signaling and aggregation—AKT1—melanoma	2.29e-06	5.66e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—SLC5A5—melanoma	2.28e-06	5.64e-05	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—melanoma	2.25e-06	5.58e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—CYP17A1—melanoma	2.25e-06	5.57e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—CUBN—melanoma	2.24e-06	5.56e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—melanoma	2.22e-06	5.5e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	2.22e-06	5.5e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—GNAQ—melanoma	2.21e-06	5.48e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—CD44—melanoma	2.21e-06	5.48e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—GNAQ—melanoma	2.2e-06	5.45e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—CD44—melanoma	2.2e-06	5.45e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—CYP17A1—melanoma	2.2e-06	5.44e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—ALB—melanoma	2.19e-06	5.43e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—IL2—melanoma	2.17e-06	5.38e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—BSG—melanoma	2.17e-06	5.37e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—SDHD—melanoma	2.17e-06	5.37e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—CSPG4—melanoma	2.17e-06	5.37e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	2.17e-06	5.37e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	2.15e-06	5.34e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—melanoma	2.15e-06	5.32e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism of lipids and lipoproteins—PTGS2—melanoma	2.14e-06	5.29e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—GNA11—melanoma	2.12e-06	5.26e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—CYP1B1—melanoma	2.12e-06	5.25e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—CYP1B1—melanoma	2.11e-06	5.22e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—GPAM—melanoma	2.1e-06	5.2e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—FASN—melanoma	2.08e-06	5.15e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—GNA11—melanoma	2.07e-06	5.14e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—CYP17A1—melanoma	2.05e-06	5.08e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—SLC5A5—melanoma	2.05e-06	5.07e-05	CbGpPWpGaD
Vismodegib—ABCB1—Transmembrane transport of small molecules—ALB—melanoma	2.03e-06	5.04e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—FASN—melanoma	2.03e-06	5.03e-05	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—PIK3CG—melanoma	2.03e-06	5.03e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	2.02e-06	5.01e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—ALB—melanoma	2e-06	4.95e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—SLC5A5—melanoma	2e-06	4.94e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—GNAQ—melanoma	1.98e-06	4.89e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—CD44—melanoma	1.98e-06	4.89e-05	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—PPARG—melanoma	1.96e-06	4.85e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—GNA11—melanoma	1.94e-06	4.8e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	1.93e-06	4.79e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—GNAQ—melanoma	1.93e-06	4.77e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—CD44—melanoma	1.93e-06	4.77e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—melanoma	1.92e-06	4.75e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—FASN—melanoma	1.9e-06	4.7e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—CYP1B1—melanoma	1.89e-06	4.69e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—melanoma	1.87e-06	4.64e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—SLC5A5—melanoma	1.87e-06	4.62e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism of lipids and lipoproteins—PTEN—melanoma	1.86e-06	4.61e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—CYP1B1—melanoma	1.85e-06	4.58e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—VEGFA—melanoma	1.85e-06	4.57e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—NRAS—melanoma	1.82e-06	4.52e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—GNAQ—melanoma	1.8e-06	4.46e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—CD44—melanoma	1.8e-06	4.46e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—PLA2G6—melanoma	1.79e-06	4.42e-05	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—PIK3CD—melanoma	1.78e-06	4.42e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	1.76e-06	4.37e-05	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—ALB—melanoma	1.76e-06	4.36e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—melanoma	1.75e-06	4.33e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—MAPK3—melanoma	1.75e-06	4.33e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—ABCB1—melanoma	1.75e-06	4.33e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—ABCB1—melanoma	1.74e-06	4.3e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—CYP1B1—melanoma	1.73e-06	4.28e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—melanoma	1.67e-06	4.14e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—MAPK1—melanoma	1.66e-06	4.12e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—PRKCA—melanoma	1.61e-06	3.98e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—VCAN—melanoma	1.6e-06	3.97e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—PRKCA—melanoma	1.6e-06	3.96e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—ERCC2—melanoma	1.59e-06	3.95e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—ERCC2—melanoma	1.59e-06	3.93e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—KRAS—melanoma	1.57e-06	3.89e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—ABCB1—melanoma	1.56e-06	3.86e-05	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—PIK3CB—melanoma	1.56e-06	3.85e-05	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—PTGS2—melanoma	1.54e-06	3.82e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—melanoma	1.52e-06	3.77e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—PIK3CA—melanoma	1.44e-06	3.57e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—PRKCA—melanoma	1.44e-06	3.55e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—ERCC2—melanoma	1.42e-06	3.53e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—ABCB1—melanoma	1.42e-06	3.52e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—PRKCA—melanoma	1.4e-06	3.47e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—TP53—melanoma	1.4e-06	3.46e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—ERCC2—melanoma	1.39e-06	3.44e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—CYP17A1—melanoma	1.35e-06	3.35e-05	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—PTEN—melanoma	1.34e-06	3.33e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—HRAS—melanoma	1.33e-06	3.31e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	1.32e-06	3.27e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	1.31e-06	3.25e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—PRKCA—melanoma	1.31e-06	3.24e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—ERCC2—melanoma	1.3e-06	3.21e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—GNA11—melanoma	1.28e-06	3.16e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—PIK3CG—melanoma	1.26e-06	3.12e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—PIK3CG—melanoma	1.25e-06	3.1e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—FASN—melanoma	1.25e-06	3.1e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—SLC5A5—melanoma	1.23e-06	3.05e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—PPARG—melanoma	1.22e-06	3.01e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—PPARG—melanoma	1.21e-06	2.99e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—GNAQ—melanoma	1.19e-06	2.94e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—CD44—melanoma	1.19e-06	2.94e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	1.18e-06	2.92e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—AKT1—melanoma	1.18e-06	2.92e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—CYP1B1—melanoma	1.14e-06	2.82e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—PIK3CG—melanoma	1.12e-06	2.78e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—PIK3CD—melanoma	1.11e-06	2.74e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—PIK3CD—melanoma	1.1e-06	2.73e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—PIK3CG—melanoma	1.1e-06	2.72e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—ALB—melanoma	1.09e-06	2.71e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—PPARG—melanoma	1.09e-06	2.69e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	1.08e-06	2.66e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—PPARG—melanoma	1.06e-06	2.62e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—PIK3CG—melanoma	1.03e-06	2.54e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—PPARG—melanoma	9.89e-07	2.45e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—PIK3CD—melanoma	9.88e-07	2.45e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—ALB—melanoma	9.76e-07	2.42e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—PIK3CB—melanoma	9.65e-07	2.39e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—PIK3CD—melanoma	9.65e-07	2.39e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—PIK3CB—melanoma	9.6e-07	2.38e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—PTGS2—melanoma	9.56e-07	2.37e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—ALB—melanoma	9.52e-07	2.36e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—PTGS2—melanoma	9.51e-07	2.35e-05	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—PIK3CA—melanoma	9.48e-07	2.35e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—ABCB1—melanoma	9.38e-07	2.32e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—PIK3CD—melanoma	9.01e-07	2.23e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—ALB—melanoma	8.9e-07	2.2e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—PRKCA—melanoma	8.63e-07	2.14e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—PIK3CB—melanoma	8.61e-07	2.13e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—ERCC2—melanoma	8.56e-07	2.12e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—PTGS2—melanoma	8.54e-07	2.11e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—PIK3CB—melanoma	8.41e-07	2.08e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—PTEN—melanoma	8.34e-07	2.07e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—PTGS2—melanoma	8.33e-07	2.06e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—PTEN—melanoma	8.29e-07	2.05e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—PIK3CB—melanoma	7.85e-07	1.95e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—PTGS2—melanoma	7.78e-07	1.93e-05	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—AKT1—melanoma	7.74e-07	1.92e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—PTEN—melanoma	7.44e-07	1.84e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—PTEN—melanoma	7.27e-07	1.8e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—PTEN—melanoma	6.79e-07	1.68e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—PIK3CG—melanoma	6.76e-07	1.67e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—PPARG—melanoma	6.52e-07	1.62e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—PIK3CD—melanoma	5.94e-07	1.47e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—PIK3CA—melanoma	5.88e-07	1.46e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—ALB—melanoma	5.87e-07	1.45e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—PIK3CA—melanoma	5.85e-07	1.45e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—PIK3CA—melanoma	5.25e-07	1.3e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—PIK3CB—melanoma	5.18e-07	1.28e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—PTGS2—melanoma	5.13e-07	1.27e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—PIK3CA—melanoma	5.13e-07	1.27e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—AKT1—melanoma	4.81e-07	1.19e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—PIK3CA—melanoma	4.79e-07	1.19e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—AKT1—melanoma	4.78e-07	1.18e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—PTEN—melanoma	4.48e-07	1.11e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—AKT1—melanoma	4.29e-07	1.06e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—AKT1—melanoma	4.19e-07	1.04e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—AKT1—melanoma	3.91e-07	9.69e-06	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—PIK3CA—melanoma	3.16e-07	7.82e-06	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—AKT1—melanoma	2.58e-07	6.39e-06	CbGpPWpGaD
